After-Hours Stock Movers 11/07: (ACAD) (PCLN) (NWSA) Higher; (HTZ) (KND) (DEPO) Lower (more...)

November 7, 2016 5:50 PM EST

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Today's After-Hours Movers

Hertz Global (NYSE: HTZ) 25.2% LOWER; reported Q3 EPS of $1.58, $1.17 worse than the analyst estimate of $2.75. Revenue for the quarter came in at $2.5 billion versus the consensus estimate of $2.6 billion. GUIDANCE: Hertz Global sees FY2016 EPS of $0.51-$0.88, versus the consensus of $2.94.

Kindred Healthcare (NYSE: KND) 16% LOWER; reported Q3 EPS of $0.05, $0.01 worse than the analyst estimate of $0.06. Revenue for the quarter came in at $1.79 billion versus the consensus estimate of $1.77 billion. GUIDANCE: Kindred Healthcare sees FY2016 EPS of $0.70-$0.80, versus the consensus of $0.90. Kindred Healthcare sees FY2016 revenue of $7.2-7.3 billion, versus the consensus of $7.22 billion.

Depomed (NASDAQ: DEPO) 12.6% LOWER; reported Q3 EPS of $0.28, $0.07 worse than the analyst estimate of $0.35. Revenue for the quarter came in at $111 million versus the consensus estimate of $127.22 million.

Nevro (NYSE: NVRO) 9.7% LOWER; reported Q3 EPS of ($0.14), $0.26 better than the analyst estimate of ($0.40). Revenue for the quarter came in at $60.9 million versus the consensus estimate of $58.05 million. GUIDANCE: Nevro sees Q4 2016 revenue of $220-225 million, versus the consensus of $222.2 million.

Acadia Pharma (NASDAQ: ACAD) 9% HIGHER; reported Q3 EPS of ($0.61), $0.05 worse than the analyst estimate of ($0.56). Revenue for the quarter came in at $5.3 million versus the consensus estimate of $2.9 million. Also said they continue to expand its clinical program with pimavanserin.

Resolute Energy (NYSE: REN) 8.6% LOWER; reported Q3 EPS of ($1.24), which may not compare with the analyst estimate of $0.29. Revenue for the quarter came in at $47.42 million versus the consensus estimate of $62.91 million. Adjusted EBITDA was $40.3 million, versus $30.8 million posted in the same period last year.

Fabrinet (NYSE: FN) 8.2% HIGHER; reported Q1 EPS of $0.80, $0.09 better than the analyst estimate of $0.71. Revenue for the quarter came in at $332 million versus the consensus estimate of $309.44 million. GUIDANCE: Fabrinet sees Q2 2017 EPS of $0.78-$0.80, versus the consensus of $0.69. Fabrinet sees Q2 2017 revenue of $332-336 million, versus the consensus of $305.3 million.

Cray (NASDAQ: CRAY) 7.7% LOWER; reported Q3 EPS of ($0.49), $0.15 worse than the analyst estimate of ($0.34). Revenue for the quarter came in at $77.5 million versus the consensus estimate of $79.53 million. GUIDANCE: Cray sees FY2016 revenue of $620-650 million, versus the consensus of $649.6 million. GAAP and Non-GAAP gross margin for the year is expected to be in the range of 34%

The Medicines Company (NASDAQ: MDCO) 6.2% LOWER; announced today the immediate discontinuation of the clinical development program for MDCO-216, its investigational cholesterol efflux promoter. Data from the recently-completed MILANO-PILOT trial did not show drug effects on intracoronary atherosclerotic plaque sufficient to warrant further development. The safety profile of MDCO-216 was excellent.

The Priceline Group (NASDAQ: PCLN) 5% HIGHER; reported Q3 EPS of $31.18, $1.86 better than the analyst estimate of $29.32. Revenue for the quarter came in at $3.69 billion versus the consensus estimate of $3.62 billion. he Priceline Group sees Q4 2016 EPS of $12.20-$12.80, versus the consensus of $12.93.

News Corp (NASDAQ: NWSA) (NYSE: NWS) 3.9% HIGHER; reported Q1 EPS of ($0.01), versus $0.05 reported last year. Revenue for the quarter came in at $1.97 billion versus the consensus estimate of $1.96 billion.

Marriott (NASDAQ: MAR) 2.2% LOWER; reported Q3 EPS of $0.91, $0.02 better than the analyst estimate of $0.89. Revenue for the quarter came in at $3.94 billion versus the consensus estimate of $4.15 billion. Third quarter worldwide incentive management fees increased 19 percent to $81 million, primarily due to $4 million related to the eight days of Starwood's results in the quarter, higher RevPAR and house profit margins, as well as increased international distribution, partially offset by $2 million of unfavorable foreign exchange. GUIDANCE: Marriott sees Q4 2016 EPS of $0.80-$0.85, versus the consensus of $0.88.

Microchip Technology (NASDAQ: MCHP) 1.2% HIGHER; reported Q2 EPS of $0.94, $0.07 better than the analyst estimate of $0.87. Revenue for the quarter came in at $871.4 million versus the consensus estimate of $860.96 million. GUIDANCE: Microchip Technology sees Q3 2017 EPS of $0.85-$0.95, versus the consensus of $0.83. Microchip Technology sees Q3 2017 revenue of $821.4-873.8 million, versus the consensus of $844.58 million.

Mylan NV (NYSE: MYL) 1% LOWER; The U.S. Senate Judiciary Committee urged federal antitrust regulators on Monday to launch a probe into whether EpiPen maker Mylan NV broke the law by preventing schools from purchasing competing allergy treatments



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Special Reports

Related Entities

After-Hours Movers

Add Your Comment